Literature DB >> 7207635

The locomotor effect of clonidine and its interaction with alpha-flupenthixol or haloperidol in the developing rat.

Y Nomura.   

Abstract

The interaction of clonidine with alpha-flupenthixol and haloperidol on the locomotion was investigation in the rat during postnatal development. A subcutaneous injection of clonidine 0.039--3.9 mu mol/kg produced a marked hypermotility in infant animals between day 1 and day 7 but hypomotility in animals older than 20 days. Pretreatment with alpha-flupenthixol and haloperidol significantly reduced clonidine-hypermotility in infants. In adult rats, clonidine-hypomotility were increased by a preceding administration of alpha-flupenthixol. It is suggested that intact function of both alpha-adrenoceptors and dopamine receptors is involved in the control of locomotor activity in developing rats and that there is the complex interaction of noradrenergic and dopaminergic system in the control of locomotor activity.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7207635     DOI: 10.1007/bf00505802

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  20 in total

1.  Possible involvement of central histamine H2-receptors in the hypotensive effect of clonidine.

Authors:  H Karppanen; I Paakkari; P Paakkari; R Huotari; A L Orma
Journal:  Nature       Date:  1976-02-19       Impact factor: 49.962

2.  Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain.

Authors:  S J Peroutka; D C U'Prichard; D A Greenberg; S H Snyder
Journal:  Neuropharmacology       Date:  1977-09       Impact factor: 5.250

3.  Clonidine-induced hypotension: further evidence for a central interaction with histamine H2 receptor antagonists in the rat.

Authors:  L Finch; C A Harvey; P E Hicks; D A Owen
Journal:  Neuropharmacology       Date:  1978 Apr-May       Impact factor: 5.250

4.  An ontogenic study on the effect of catecholamine receptor-stimulating agents on the turnover of noradrenaline and dopamine in the brain.

Authors:  C Kellogg; G Wennerström
Journal:  Brain Res       Date:  1974-10-25       Impact factor: 3.252

5.  Ontogenic variations in responses to L-DOPA and monoamine receptor-stimulating agents.

Authors:  C Kellogg; P Lundborg
Journal:  Psychopharmacologia       Date:  1972

6.  The development of responsiveness to dopaminergic agonists.

Authors:  D K Reinstein; D McClearn; R L Isaacson
Journal:  Brain Res       Date:  1978-07-07       Impact factor: 3.252

7.  The effect of alpha-adrenoceptor antagonists and metiamide on clonidine-induced locomotor stimulation in the infant rat.

Authors:  Y Nomura; T Segawa
Journal:  Br J Pharmacol       Date:  1979-08       Impact factor: 8.739

8.  Histamine H2-receptors in the brain and sleep produced by clonidine.

Authors:  M Vogt
Journal:  Br J Pharmacol       Date:  1977-11       Impact factor: 8.739

9.  Ontogeny of adrenergic arousal and cholinergic inhibitory mechanisms in the rat.

Authors:  B A Campbell; L D Lytle; H C Fibiger
Journal:  Science       Date:  1969-10-31       Impact factor: 47.728

10.  Further evidence for central histamine H2-receptor involvement in the hypotensive effect of clonidine in the rat.

Authors:  H Karppanen; I Paakkari; P Paakkari
Journal:  Eur J Pharmacol       Date:  1977-04-07       Impact factor: 4.432

View more
  3 in total

1.  Effect of clonidine on ultrasonic vocalization in preweaning rats.

Authors:  E Hård; J Engel; A S Lindh
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

2.  Early postnatal clonidine treatment results in altered regional catecholamine utilisation in adult rat brain.

Authors:  M G Feenstra; H van Galen; G J Boer
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Clonidine treatment delays postnatal motor development and blocks short-term memory in young mice.

Authors:  Cristina Calvino-Núñez; Eduardo Domínguez-del-Toro
Journal:  PLoS One       Date:  2014-12-22       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.